In addition to traditional in-licensing opportunities, our activities include acquisitions, risk sharing deals, spin-outs, equity stakes, divestments and out-licensing deals.
No two deals are the same. We work in collaboration to structure customised partnerships that allow both parties to leverage their unique capabilities and assets to achieve common goals.
Our Strategic Partnering & Business Development team supports the delivery of this key strategic priority through a globally integrated organisation.
Below is a selection of news releases describing recent deals completed by AstraZeneca and our biologics arm, MedImmune. This highlights our creative approach to forging mutually beneficial relationships.
Partnering news
- Thursday, 26 January 2012
- AstraZeneca and Karolinska Institutet PET Centre Announce Molecular Imaging Research Agreement AstraZeneca and Karolinska Institutet today announced a three year collaborative research agreement that will apply state-of-the-art molecular imaging technologies to generate novel diagnostic imaging tools and further the development of AstraZeneca’s neuroscience research and development pipeline.
- Wednesday, 11 January 2012
- AstraZeneca and IMS Health announce real-world evidence collaboration in Europe AstraZeneca today announced that it has entered into a three-year collaboration agreement with IMS Health, the leading provider of information, services and technology for the healthcare sector, to advance the use of real-world evidence based on observational and retrospective studies throughout Europe to inform the delivery of effective and cost-efficient healthcare.
- Thursday, 5 January 2012
- Targacept announces decision by AstraZeneca to advance AZD1446 in Alzheimer’s disease Targacept, Inc., a clinical-stage biopharmaceutical company developing novel NNR Therapeutics™, today announced that AstraZeneca has informed the company that it plans to progress the development of Targacept’s product candidate AZD1446 as a treatment for Alzheimer’s disease.